Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to 499.94%.

  • Sutro Biopharma's EBITDA Margin rose 2972300.0% to 499.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 197.53%, marking a year-over-year decrease of 1125600.0%. This contributed to the annual value of 384.34% for FY2024, which is 3262600.0% down from last year.
  • Sutro Biopharma's EBITDA Margin amounted to 499.94% in Q3 2025, which was up 2972300.0% from 5.25% recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's EBITDA Margin peaked at 37.95% during Q4 2023, and registered a low of 1202.0% during Q1 2025.
  • Its 5-year average for EBITDA Margin is 365.27%, with a median of 333.26% in 2023.
  • As far as peak fluctuations go, Sutro Biopharma's EBITDA Margin skyrocketed by 6081700bps in 2023, and later crashed by -7669500bps in 2025.
  • Sutro Biopharma's EBITDA Margin (Quarter) stood at 328.85% in 2021, then tumbled by -73bps to 570.23% in 2022, then surged by 107bps to 37.95% in 2023, then crashed by -1261bps to 440.66% in 2024, then fell by -13bps to 499.94% in 2025.
  • Its EBITDA Margin was 499.94% in Q3 2025, compared to 5.25% in Q2 2025 and 1202.0% in Q1 2025.